Assessing minimal residual disease (MRD) in leukemia: A changing definition and concept?

Bone Marrow Transplantation

Volumn 29, Issue 6, 2002, Pages 459-465

  Paietta, E ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Minimal residual disease; New definitions

Indexed keywords

ANTILEUKEMIC AGENT; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID; TUMOR MARKER;

ACUTE LYMPHOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; BONE MARROW PURGING; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 4; CHROMOSOME TRANSLOCATION 8; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DIAGNOSTIC VALUE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; KARYOTYPING; LEUKEMIA REMISSION; MINIMAL RESIDUAL DISEASE; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENCE RISK; SHORT SURVEY; TREATMENT OUTCOME; TREATMENT PLANNING;

CYTODIAGNOSIS; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA; MOLECULAR DIAGNOSTIC TECHNIQUES; MONITORING, IMMUNOLOGIC; NEOPLASM, RESIDUAL;

EID: 0036236968     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703388     Document Type: Short Survey

References (65)

1. Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR
2. Cytogenetic alterations and related molecular consequences in adult leukemia
3. Flow cytometry and allele-specific oligonucleotide PCR are equally effective in detection of minimal residual disease in ALL
4. Detection of minimal residual disease in acute leukemia by flow cytometry
5. World Health Organization Classification of Tumors: Tumors of Hematopoietic and Lymphoid Tissues
6. Immunobiology of acute leukemia
7. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia
8. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification
9. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia
10. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse
11. Quantification of CBFβ/MYH11 fusion transcript by real-time RT-PCR in patients with inv(16) acute myeloid leukemia
12. Monitoring minimal residual disease and predicting relapse in APL by quantitating PML-RARα transcripts with a sensitive competitive RT-PCR method
13. Quantification of minimal residual disease in children with oligoclonal B-precursor acute lymphoblastic leukemia indicates that the clones that grow out during relapse already have the slowest rate of reduction during therapy
14. Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?
15. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia
16. Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: A multicenter study of 51 patients
17. New definition of remission in childhood acute lymphoblastic leukemia
18. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients 'late', 18 months or more after transplantation
19. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease
20. Comparative analysis of minimal residual disease in peripheral blood versus bone marrow in childhood acute lymphoblastic leukemia
21. Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation
22. Do transcriptionally silent BCR/ABL cells persist in CML patients in molecular remission after stem cell transplantation
23. Comparison of methods for assessment of minimal residual disease in childhood B-lineage acute lymphoblastic leukemia
24. T-lymphocytes in bone marrow samples of children with acute lymphoblastic leukemia during and after chemotherapy might hamper PCR-based minimal residual disease studies
25. Debate Round Table on RT-PCR controls: Concluding remarks and mini-review. Current recommendations for positive controls in RT-PCR assays
26. Detection of minimal residual disease in acute myeloid leukemia: Methodologies, clinical and biological significance
27. Clinically useful information provided by the flow cytometric immunophenotyping of hematological malignancies: Current status and future directions
28. A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: Implications for residual disease detection
29. Leukemia-associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukemia: Detection in remission marrow predicts outcome
30. BIOMED-I concerted action report: Flow cytometric immunophenotyping of precursor B-ALL with standardized triple-staining
31. Prognostic significance of immunophenotyping and cytogenetics in adult acute lymphoblastic leukemia (ALL): Interim analysis of ECOG/MRC phase III intergroup trial, E2993
32. Probing the pathobiology of response to all-trans retinoic acid in acute promyelocytic leukemia: Premature chromosome condensation/fluorescence in situ hybridization analysis
33. Interstitial insertion of retinoic acid receptor-α gene in acute promyelocytic leukemia with normal chromosomes 15 and 17
34. Comparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/ETO fusion transcript found only by PCR testing
35. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: A Cancer and Leukemia Group B study
36. Clinical significance of MLL-AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;11)(q21;q23) chromosomal translocation
37. The pathogenesis of acute promyelocytic leukemia: Evaluation of the role of molecular diagnosis and monitoring in the management of the disease
38. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: From the United Kingdom Medical Research Council AML 10 and 12 trials
39. Analysis of FLT3-activating mutations in 713 patients with acute myelogenous leukemia (AML): High prevalence in FAB-subtype M5 and identification of subgroups with poor prognosis
40. FLT3 internal tandem duplications and survival in adult acute myeloid leukemia: Analysis of 188 intensively treated patients
41. Quantitative, real-time polymerase chain reactions for FLT3 internal tandem duplications are highly sensitive and specific
42. Changes in the pattern of FLT3 mutations between diagnosis and relapse restricts their potential use as markers of minimal residual disease in patients with acute myeloid leukemia
43. Detection of minimal residual disease in acute lymphoblastic leukemia: The St Jude experience
44. Heterogeneity of VH-JH gene rearrangement patterns: An insight into the biology of B cell precursor ALL
45. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group
46. Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia
47. The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia
48. Molecular quantification of response to therapy and remission status in TEL-AML1-positive childhood ALL by real-time reverse transcription polymerase chain reaction
49. Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: Low levels of minimal residual disease are associated with continuing remission
50. New approaches to chronic myelogenous leukemia
51. Molecular evidence for minimal residual bone marrow disease in children with 'isolated' extra-medullary relapse of T cell acute lymphoblastic leukemia
52. PCR assessment of bone marrow status in 'isolated' extramedullary relapse of childhood B-precursor acute lymphoblastic leukemia
53. Correlation of bone marrow minimal residual disease and apparent isolated extramedullary relapse in childhood acute lymphoblastic leukemia
54. The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction methods in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage
55. Detection and quantification of residual disease in chronic myelogenous leukemia
56. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia
57. Quantitative analysis of AML1/ETO transcripts in peripheral blood stem cell harvests from patients with t(8;21) acute myelogenous leukemia
58. Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation
59. Transplant characteristics: Minimal residual disease and impaired megakaryocytic colony growth as sensitive parameters for predicting relapse in acute myeloid leukemia
60. Leukemogenesis by CBF oncoproteins
61. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation
62. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals
63. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biological significance and implications for the assessment of minimal residual disease
64. PML-RARA fusion transcripts in irradiated and normal hematopoietic cells
65. Shifting the cancer paradigm: Must we kill to cure?